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AbstrAct
Objective
To assess the effectiveness of pelvic floor muscle 
training (PFMT) plus electromyographic biofeedback 
or PFMT alone for stress or mixed urinary incontinence 
in women.
Design
Parallel group randomised controlled trial.
setting
23 community and secondary care centres providing 
continence care in Scotland and England.
ParticiPants
600 women aged 18 and older, newly presenting with 
stress or mixed urinary incontinence between February 
2014 and July 2016: 300 were randomised to PFMT 
plus electromyographic biofeedback and 300 to PFMT 
alone.
interventiOns
Participants in both groups were offered six 
appointments with a continence therapist over 
16 weeks. Participants in the biofeedback PFMT 
group received supervised PFMT and a home PFMT 
programme, incorporating electromyographic 
biofeedback during clinic appointments and at home. 
The PFMT group received supervised PFMT and a home 
PFMT programme. PFMT programmes were progressed 
over the appointments.
Main OutcOMe Measures
The primary outcome was self-reported severity of 
urinary incontinence (International Consultation on 
Incontinence Questionnaire-urinary incontinence 
short form (ICIQ-UI SF), range 0 to 21, higher scores 
indicating greater severity) at 24 months. Secondary 
outcomes were cure or improvement, other pelvic 
floor symptoms, condition specific quality of life, 
women’s perception of improvement, pelvic floor 
muscle function, uptake of other urinary incontinence 
treatment, PFMT self-efficacy, adherence, intervention 
costs, and quality adjusted life years.
results
Mean ICIQ-UI SF scores at 24 months were 8.2 (SD 
5.1, n=225) in the biofeedback PFMT group and 8.5 
(SD 4.9, n=235) in the PFMT group (mean difference 
−0.09, 95% confidence interval −0.92 to 0.75, 
P=0.84). Biofeedback PFMT had similar costs (mean 
difference £121 ($154; €133), −£409 to £651, 
P=0.64) and quality adjusted life years (−0.04, −0.12 
to 0.04, P=0.28) to PFMT. 48 participants reported 
an adverse event: for 23 this was related or possibly 
related to the interventions.
cOnclusiOns
At 24 months no evidence was found of any important 
difference in severity of urinary incontinence between 
PFMT plus electromyographic biofeedback and PFMT 
alone groups. Routine use of electromyographic 
biofeedback with PFMT should not be recommended. 
Other ways of maximising the effects of PFMT should 
be investigated.
trial registratiOn
ISRCTN57756448.
Introduction
Urinary incontinence, defined as involuntary urine 
leakage,1 is a distressing, socially restricting condition 
that affects about one in three women. Urinary 
incontinence is categorised into three subcategories: 
stress urinary incontinence, the most common type, 
concerns urine leakage associated with physical 
exertion, coughing, and sneezing; urgency urinary 
incontinence involves a sudden need to pass urine, 
which is preceded or accompanied by urine leakage; 
and mixed urinary incontinence involves both stress 
and urgency urinary incontinence. Regular and 
progressive pelvic floor muscle training (PFMT) for 
three months is currently recommended in the United 
Kingdom for stress and mixed urinary incontinence2 to 
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WhAt Is AlreAdy knoWn on thIs topIc
The 2011 Cochrane review assessing the benefit of adding feedback to PFMT for 
female urinary incontinence included 16 trials, but seven reported more PFMT 
supervision in the biofeedback group
The results differed depending on whether trial groups had comparable PFMT 
programmes; it was concluded that biofeedback might provide benefit but 
further research was needed
Since then a meta-analysis including 11 trials concluded no benefit from adding 
biofeedback to PFMT, whereas two subsequent small single centre trials found 
some benefit of biofeedback immediately post-treatment
WhAt thIs study Adds
This trial did not show a statistically significant or clinically important difference 
in severity of urinary incontinence at 24 months between women randomised to 
electromyographic biofeedback PFMT or to PFMT alone
This trial confirms that routine use of electromyographic biofeedback with PFMT 
for women with stress or mixed urinary incontinence does not provide additional 
benefit
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improve pelvic floor muscle function and its role in the 
continence mechanism.3 Cochrane review evidence 
shows effectiveness of PFMT for urinary incontinence.4
Adjuncts commonly used clinically to increase 
the effects of PFMT include electromyographic bio­
feedback, weighted vaginal cones, and electrical 
stimulation. Electromyographic biofeedback uses a 
vaginal probe to capture the electrical activity of the 
pelvic floor muscles, which is displayed on a screen. 
Used in tandem with PFMT, electromyographic bio­
feedback aims to facilitate teaching of the correct 
contraction technique and home exercise programme. 
Additionally, biofeedback allows women to visualise 
the activity of their pelvic floor muscles while 
exercising, potentially motivating them and enhancing 
adherence to the prescribed exercises.
A Cochrane review synthesised the evidence for the 
benefit of PFMT with device mediated biofeedback over 
PFMT alone and although it seemed biofeedback might 
be more effective than PFMT alone, many comparisons 
were confounded.5 Alternative plausible explanations 
were that participants receiving biofeedback had 
longer treatment times, more therapist contact, and 
different PFMT programmes. It was therefore unclear 
whether biofeedback provided additional benefit over 
PFMT alone. In this trial (OPAL, Optimal PFMT for 
Adherence Long term), we assessed whether PFMT 
plus electromyographic biofeedback in the clinic and 
at home would be more effective than PFMT alone for 
reducing the severity of incontinence in women with 
stress or mixed urinary incontinence.
Methods
study design and participants
Our multicentre, parallel group randomised controlled 
trial was conducted in 23 UK centres providing 
continence care, with participant recruitment between 
February 2014 and July 2016.6 All the centres used 
electromyographic biofeedback to varying degrees 
before the trial. Women aged 18 years or older and 
newly presenting with clinically diagnosed stress 
or mixed urinary incontinence and urine leakage 
as the primary problem were potentially eligible for 
inclusion. We excluded participants who had urgency 
urinary incontinence alone, a prolapse greater than 
stage II on examination (>1cm below the hymen on 
straining), were unable to contract pelvic floor muscles 
on digital examination when requested, had received 
formal instruction on PFMT in the preceding year (this 
was originally three years but was changed on 1 June 
2015), were pregnant or had given birth in the past six 
months (this was originally one year but was changed 
on 1 June 2015), were receiving treatment for pelvic 
cancer, had neurological disease, could not provide 
informed consent because of cognitive impairment, 
were allergic or sensitive to nickel (this was added on 
1 June 2015), or were participating in other urinary 
incontinence research. We originally excluded women 
who were using antimuscarinic drugs but removed this 
criterion before the start of recruitment (4 February 
2014) because this is a common treatment for women 
with mixed urinary incontinence. All participants gave 
verbal and written informed consent.
randomisation and masking
The Centre for Healthcare Randomised Trials, University 
of Aberdeen, carried out the web based randomisation, 
with participants assigned in a ratio of 1:1 to either 
PFMT with clinic and home electromyographic 
biofeedback or PFMT alone. Randomisation was 
minimised by urinary incontinence type (stress v 
mixed), recruiting centre, age (<50 v ≥50 years), 
and severity of urinary incontinence (International 
Consultation on Incontinence Questionnaire­urinary 
incontinence short form (ICIQ­UI SF) score of <13 v 
≥13).7 Group allocation was relayed to participants 
by letter and to the trial office and recruiting centre 
by email. Participants, therapists delivering the 
intervention, and research staff could not be masked 
to group allocation. However, clinicians performing 
the six month pelvic floor muscle assessment were 
masked.
Procedures
Participants in both groups were offered six face­to­
face appointments (weeks 0, 1, 3, 6, 10, and 15; 60 
minutes for the first appointment and 30 minutes 
for subsequent appointments) with a therapist 
(an experienced physiotherapist, nurse, or other 
continence clinician) who had received training in 
intervention delivery. The therapist assessed the 
pelvic floor muscles, taught the correct technique 
for exercise, prescribed an individualised PFMT 
programme to be followed at home (aiming for three 
sets of exercises daily, recorded in an exercise diary), 
and used behaviour change techniques8 embedded in 
the protocols to encourage adherence.6 Bladder and 
bowel management information and lifestyle advice 
were provided as necessary. For participants in the 
biofeedback and PFMT group, electromyographic 
biofeedback was integrated with PFMT during the 
appointments. In addition, participants in this group 
were given the same biofeedback device as used during 
appointments for their home use with a prescribed 
programme, along with information on operating, 
cleaning, and output interpretation. The devices stored 
usage information and the participants recorded the 
use of the biofeedback device in their exercise diaries. 
We selected the electromyographic biofeedback device 
most used in the UK national health service at the 
time of the trial, and all centres were provided with an 
adequate supply of this device. By standardising and 
protocolising the PFMT delivered in both groups we 
ensured that all participants had the same treatment 
other than the addition of the electromyographic 
biofeedback.
For each participant, the therapist recorded age, 
body mass index, number of births and delivery type, 
and urinary incontinence type and severity (using 
two ICIQ­UI SF questions relating to frequency and 
volume of leakage). The women used a bladder diary 
to record baseline urine leakage over three days. At 
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each appointment, therapists recorded the findings of 
clinical assessment, treatment plan, prescribed PFMT 
programme, and participant’s adherence. Participants 
completed questionnaires at baseline and at 6, 12, 
and 24 months. A clinician not involved in treatment 
delivery and masked to group allocation carried out a 
pelvic floor muscle assessment at six months.
Outcomes
The primary outcome was severity of urinary in­
continence (ICIQ­UI SF)9 at 24 months. The ICIQ­
UI SF score ranges from 0 to 21 and is the weighted 
sum of three items addressing urinary incontinence 
frequency (“how often do you leak urine?” 0=never to 
5=all the time), leakage quantity (“how much urine do 
you usually leak?” 0=none to 6=a large amount), and 
interference with everyday life (0=not at all to 10=a 
great deal). Higher scores reflect greater severity.
Secondary outcomes were cure (never or none 
responses to ICIQ­UI SF frequency or quantity items) 
and improvement in urinary incontinence (reduction 
in ICIQ­UI SF score of ≥3 points),10 the Patient Global 
Impression of Improvement, measuring participants’ 
perceptions of their urine leakage (1=very much 
better to 7=very much worse),11 uptake of urinary 
incontinence treatment (surgical or non­surgical), 
the International Consultation on Incontinence 
Questionnaire­female lower urinary tract symptoms 
(12 items, three subscales: filling (0­15), voiding (0­
12), and incontinence (0­20), higher scores worse),12 
the International Consultation on Incontinence 
Questionnaire­lower urinary tract symptoms quality 
of life (19 items, total ranging from 19 to 76, higher 
scores worse),13 the EuroQol­5 dimension­3 level (EQ­
5D­3L) questionnaire (range −0.594 to 1) and EQ­5D 
visual analogue scale (range 0 to 100, higher scores 
better),14 the pelvic organ prolapse symptom score 
(POP­SS; seven items, total ranging from 0 to 28, 
higher scores worse),15 an early non­validated version 
of the International Consultation on Incontinence 
Questionnaire­bowel short form (six items: difficulty 
emptying, urgency, leakage, frequency of defecation, 
stool consistency, and interference with everyday life, 
each scored individually), the Oxford classification 
for pelvic floor muscle strength (0=no contraction to 
5=strong contraction),16 the International Continence 
Society classification for pelvic floor muscle relaxation 
(absent, partial, complete) and contraction (absent, 
weak, normal, strong),17 the Pelvic Floor Muscle 
Exercise Self­Efficacy scale (17 items, total ranging 
from 17 to 85, higher scores greater self­efficacy),18 
adherence to the home programme (PFMT with 
or without biofeedback as appropriate) recorded 
by the therapist at each appointment (programme 
followed, yes or no), and, if missing, ascertained 
from participant exercise diaries and biofeedback 
unit data, and adherence to PFMT longer term self­
reported in follow­up questionnaires. To quantify 
urine leakage, participants were originally asked to 
complete and return a three day bladder diary along 
with their 24 month questionnaire: this was stopped 
because of poor response, with initially only a few 
participants returning diaries or questionnaires, which 
affected the completeness of the primary outcome 
data.
We recorded all adverse and serious adverse 
events, with details of seriousness, relatedness to the 
interventions, and whether expected (as prespecified 
in the trial protocol).
statistical analysis
Analyses were prespecified (www.journalslibrary.
nihr.ac.uk/programmes/hta/117103/#/). As no 
published long term data on our primary outcome 
measure were available, we based our sample size 
calculation on studies reporting baseline ICIQ­UI 
SF scores for women with stress and mixed urinary 
incontinence.19 20 Assuming a higher standard devia­
tion of 10 at 24 months to reflect the long follow­up, 
we estimated that 234 participants in each group 
would provide 90% power at a 5% level of significance 
(two sided) to detect a between group difference of 3 
points in the ICIQ­UI SF score, which was considered 
meaningful (eg, change from leaking urine once a day 
to never). No minimal clinically important difference 
had been published for a similar population at the 
outset of the trial (only for older women, mean age 
72 years)10; however, subsequently an ICIQ­UI SF 
minimal clinically important difference of 2.5 points 
was reported in a study of younger women.21 We aimed 
to recruit 300 participants in each group, allowing for 
22% loss to follow­up.
Participant characteristics at baseline were 
summarised with counts (percentages) for dicho­
tomous and categorical variables and means (standard 
deviations) for continuous variables. We analysed 
primary and secondary outcomes by intention to treat, 
using a 5% level of significance. The mean difference 
between groups in ICIQ­UI SF at 24 months was 
estimated using a linear mixed model adjusted for 
minimisation factors, therapist type (physiotherapist 
or other), and baseline score, with recruiting centre as 
a random effect.
The potential effects of missing observations in 
the primary outcome were assessed in a multiple 
imputation model and a repeated measures model, 
both assuming that observations were missing at 
random. Additionally, we fitted pattern mixture 
models assuming observations were missing not at 
random, but were higher or lower than the imputed 
values by 2.5 points (the minimal clinically important 
difference)21 for all missing observations, and for each 
trial group separately.
In both groups we defined protocol fidelity 
(compliance) as being met if PFMT was initially 
taught with verbal feedback from vaginal palpation 
and home exercises prescribed during at least one 
appointment, along with instruction on device use in 
the biofeedback group. We investigated the influence 
of non­compliance using complier average causal 
effect models in two sensitivity analyses of the primary 
outcome, assuming that a participant’s treatment 
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was protocol compliant or non­compliant, when 
compliance status was indeterminable.
For analysis of secondary outcomes, we used 
appropriate generalised linear models (linear mixed 
models for continuous outcomes, binary logistic 
regression for dichotomous outcomes, and ordinal 
logistic regression for ordered categorical outcomes), 
adjusted for minimisation variables, therapist type, 
and baseline score if measured. We prespecified several 
subgroup analyses for the primary outcome measure, 
with a stricter 1% level of significance: incontinence 
type (stress or mixed urinary incontinence), age (<50 or 
≥50), therapist (physiotherapist or other), and baseline 
urinary incontinence severity (ICIQ­UI SF score <13 
(mild or moderate) or ≥13 (severe)).7
We assessed linearity and normality of error 
distribution assumptions through residual plots. 
When ordinal models were fitted, we examined the 
proportional odds assumption using a Brant test.
A within trial economic analysis was undertaken to 
estimate quality adjusted life years using responses 
to the EQ­5D­3L, and healthcare use reported in 
participant questionnaires, valued using published 
sources, with costs and quality adjusted life years 
discounted at the recommended rate of 3.5%.
Statistical analyses were undertaken using Stata SE 
version 14.1 (StataCorp, College Station, TX). The trial 
was overseen by a trial steering committee and data 
monitoring and ethics committee.
Patient and public involvement
A patient representative was a trial co­investigator, a 
member of the project management group, and invol­
ved from the grant writing stage through publication 
of the protocol to completion and the writing up of 
the results. In addition, she worked closely with the 
trial team on the best ways of communicating with 
participants during the recruitment and follow­up 
stages. An additional patient representative was an 
independent member of the trial steering committee. 
Involvement of these individuals provided the 
opportunity for patients to influence all aspects of 
the research, including the design and logistics of 
implementing the research. The trial was undertaken 
in response to a commissioned call from the funders, 
which was informed by a James Lind Alliance priority 
setting exercise, thus patients also informed the 
research question.
results
Between 27 February 2014 and 8 July 2016, 687 
women in 23 centres were invited to participate in the 
trial. Of these women, 600 were randomised: 300 in 
the PFMT plus electromyographic biofeedback group 
and 300 in the PFMT along group (fig 1). Participant 
personal characteristics and pelvic floor symptoms 
were similar between the groups at trial entry (table 1).
After randomisation, five participants in the 
biofeedback PFMT group and two in the PFMT group 
withdrew consent to their data being used, leaving 
295 and 298 participants included in the analysis, 
respectively (fig 1).
The proportion of participants who responded at six 
months was 74.0% (n=444/600), at 12 months was 
84.0% (n=504/600), and at 24 months was 78.0% 
(n=468/600). Overall, 53.5% (n=321/600) of women 
attended the six month blinded pelvic floor muscle 
assessment, and successful masking was recorded in 
93.5% (n=300/321). A similar proportion of women 
responded in both groups (fig 1).
One hundred and ninety eight participants (67.1%) 
in the biofeedback PFMT group and 192 (64.4%) in 
the PFMT group attended four or more appointments. 
The mean number of appointments attended was 
similar between the groups; the total time spent in 
appointments was longer for the biofeedback PFMT 
group (table 2). The intervention in both groups was 
delivered mostly by physiotherapists (table 2).
The primary outcome, ICIQ­UI SF score at 24 
months, was not statistically significantly different 
between the groups (mean difference −0.09, 95% 
confidence interval −0.92 to 0.75, P=0.84), with 
similarly no differences at six and 12 months (table 3); 
the width of all confidence intervals was less than 2.5, 
indicating no clinically important differences between 
the groups.
The results of the sensitivity analyses of the 
primary outcome to examine the effect of missing 
data (assuming missing at random) supported those 
of the primary intention­to­treat analyses (multiple 
imputation: mean difference −0.11, 95% confidence 
interval −0.95 to 0.74; repeated measures model: 
−0.08, −0.86 to 0.70). Similarly, sensitivity analyses 
assuming missing not at random and addressing 
non­compliance did not alter the conclusions (see 
supplementary file).
None of the prespecified subgroup analyses (type of 
urinary incontinence, age, baseline severity of urinary 
incontinence, therapist type) of the primary outcome 
revealed any statistically significant treatment by 
subgroup interactions (fig 2).
Based on responses to the ICIQ­UI SF, the number 
of women with cure at 24 months was not statistically 
significantly different between the biofeedback PFMT 
and PFMT groups (7.9% v 8.4%, odds ratio 0.90, 95% 
confidence interval 0.46 to 1.78, P=0.77) (table 4). 
Similarly, no statistically significant difference was 
found in the percentage of women who improved 
(60.0% v 62.6%, 0.89, 0.61 to 1.32, P=0.57) (table 4). 
Participants’ perceptions of improvement, captured 
by the Patient Global Impression of Improvement 
instrument, showed no statistically significant diffe­
rence between the groups at 24 months: 41.0% and 
38.1% reported that their symptoms were “very much 
better” or “much better” (1.12, 0.76 to 1.63, P=0.57) 
(table 4). Responses to the question “How often do you 
leak urine?” were similar between the groups at the 24 
month follow­up, the most common response being 
“about once a week or less often” (30.3% biofeedback 
PFMT v 30.4% PFMT) (see supplementary file).
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Lower urinary tract symptoms were not statistically 
significantly different between groups at 24 months 
on any of the subscale scores of filling, voiding, or 
incontinence (table 5). Quality of life related to lower 
urinary tract symptoms was not significantly different 
between groups at 24 months, measured either by the 
overall International Consultation on Incontinence 
Questionnaire­lower urinary tract symptoms quality of 
Screened
Excluded
Ineligible
  Unable to contract PFM
  Nickel allergy
  Prolapse >stage II, pelvic cancer, cognitive
    impairment, or neurological disease
  Urgency UI alone
  Formal instruction in PFMT
  Pregnant or <1 year postnatal
  Antimuscarinic drugs
  Participating in other research relating to UI
Declined
51
36
PFMTBiofeedback PFMT
18
16
7
6
3
1
0
0
184   Long 37   Short
Randomised
Blinded (91%)
687
600
87
300
Responded to baseline questionnaire (97%)
292
Withdrew consent for data to be used in analysis
Responded to baseline questionnaire (99%)
297
Attended one or more appointments (95%)
279
Attended one or more appointments (89%)
265
Attended 6 month PFM assessment (51%)
154
140
Blinded (96%)
Attended 6 month PFM assessment (56%)
167
160
Responded to 6 month questionnaire (74%)
221
180   Long 43   Short
Responded to 6 month questionnaire (74%)
223
190   Long 60   Short
Responded to 12 month questionnaire (83%)
250
187   Long 67   Short
Responded to 12 month questionnaire (85%)
254
167   Long 63   Short
Responded to 24 month questionnaire (77%)
230
171   Long 67   Short
Responded to 24 month questionnaire (79%)
238
300
5
Withdrew consent for data to be used in analysis
2
Fig 1 | trial profile. short=shortened version of questionnaire, including the international consultation on 
incontinence Questionnaire-urinary incontinence short form, the euroQol-5 dimension-3 level questionnaire, and 
questions about adherence to pelvic floor muscle training (PFMt) and uptake of urinary incontinence (ui) treatment, 
offered at the reminder stage; long=full version of questionnaire. PFM=pelvic floor muscles
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life score or by its separate scale for interference due to 
urinary symptoms (table 5).
Blinded assessment of pelvic floor muscles at six 
months showed that 8.5% (n=13) of women in the 
biofeedback PFMT group and 6.0% (n=10) in the PFMT 
group had the maximum contraction strength, with no 
statistically significant difference between the groups 
(1.28, 0.86 to 1.89, P=0.22) (table 6). Contraction 
endurance and number of repetitions to muscle fatigue 
were also similar between groups (table 6).
Prolapse symptom severity (POP­SS score) was 
not statistically significantly different between the 
biofeedback PFMT (mean 4.5 (SD 5.0)) and PFMT 
(mean 4.9 (SD 5.0)) groups at 24 months (mean 
difference −0.6, 95% confidence interval −1.51 to 
0.30, P=0.19). Bowel symptoms at 24 months were 
similar between groups (see supplementary file).
A statistically significant difference in overall score 
for PFMT self­efficacy favoured biofeedback PFMT: 
mean 63.1 (SD 11.6) biofeedback PFMT v 60.9 (SD 
12.0) PFMT (mean difference 2.36, 95% confidence 
interval 0.04 to 4.68, P=0.05).
Evidence suggested that the prescribed home 
programme was followed in at least one period 
between appointments in 78.3% (220/281) of 
participants in the biofeedback PFMT group and 
81.1% (241/297) in the PFMT group (odds ratio 
0.71, 95% confidence interval 0.43 to 1.16, P=0.17). 
At 24 months, the proportion of participants who 
reported exercising two or three times a week (as 
recommended for maintenance) was 49.1% (85/173) 
in the biofeedback PFMT group and 42.6% (80/188) in 
the PFMT group (1.20, 0.83 to 1.74, P=0.33, post hoc 
analysis).
Forty eight participants reported adverse events 
(34 biofeedback PFMT, 14 PFMT), of whom 23 (21 
biofeedback PFMT, 2 PFMT) had an event related or 
possibly related to the trial interventions. All but four 
of these events (two in each group) were expected. 
Only one event was related to the interventions: a 
nickel allergy in a participant in the biofeedback PFMT 
group, who discontinued with the intervention. In 
addition, eight serious adverse events were reported (6 
biofeedback PFMT, 2 PFMT). All were unrelated to the 
interventions and unexpected.
table 1 | baseline characteristics of participants assigned to pelvic floor muscle training (PFMt) with electromyographic 
biofeedback or to PFMt alone. values are numbers (percentages) unless stated otherwise
characteristics biofeedback PFMt PFMt
No of women, mean (SD) age (years) 300, 48.2 (11.6) 300, 47.3 (11.4)
No of women, mean (SD) body mass index 290, 28.6 (5.9) 287, 28.3 (6.2)
No of births: n=298 n=289
 0 21 (7.0) 12 (4.2)
 1 40 (13.4) 60 (20.8)
 2 116 (38.9) 122 (42.2)
 3 83 (27.9) 63 (21.8)
 ≥4 38 (12.8) 32 (11.1)
Type of incontinence: n=300 n=300
 Stress 116 (38.7) 116 (38.7)
 Mixed (stress more troublesome) 108 (36.0) 109 (36.2)
 Mixed (stress and urgency equally troublesome) 42 (14.0) 42 (14.0)
 Mixed (urgency more troublesome) 34 (11.3) 33 (11.2)
No of women, mean (SD) ICIQ-UI SF* 291, 12.5 (4.1) 294, 12.3 (3.7)
ICIQ-UI SF severity*: n=291 n=294
 Mild or moderate (<13) 140 (48.1) 149 (50.7)
 Severe (≥13) 151 (51.9) 145 (49.3)
No of women, mean (SD) No of daily episodes of incontinence† 207, 2.4 (2.8) 208, 2.2 (2.8)
No of women, mean (SD) POP-SS 274, 6.4 (5.7) 286, 6.7 (5.6)
Difficulty emptying bowels: n=289 n=296
 Never 85 (29.4) 79 (26.7)
 Occasionally 101 (34.9) 94 (31.8)
 Sometimes 68 (23.5) 83 (28.0)
 Most of the time 25 (8.7) 26 (8.8)
 All of the time 10 (3.5) 14 (4.7)
ICIQ-UI SF=International Consultation on Incontinence Questionnaire-urinary incontinence short form; POP-SS=pelvic organ prolapse symptom score.
*ICIQ-UI SF as reported in the participant’s baseline questionnaire, rather than the web based randomisation system, which was used for the purpose of 
minimisation.
†Based on three day bladder diary.
table 2 | appointment attendance in participants assigned to pelvic floor muscle training 
(PFMt) with electromyographic biofeedback or to PFMt alone, and therapist type. values 
are numbers (percentages) unless stated otherwise
attendance and therapist type biofeedback PFMt (n=295) PFMt (n=298)
No of appointments attended:
 0 16 (5.4) 33 (11.1)
 1 20 (6.8) 18 (6.0)
 2 24 (8.1) 22 (7.4)
 3 37 (12.5) 33 (11.1)
 4 33 (11.2) 22 (7.4)
 5 56 (19.0) 64 (21.5)
 6 109 (36.9) 106 (35.6)
Mean (SD) total No of appointments 4.2 (1.9) 4 (2.1)
Mean (SD) total duration of appointments (mins) 176 (84) 152 (78)
Type of therapist:
 Physiotherapist 256 (86.8) 247 (82.9)
 Nurse 17 (5.8) 11 (3.7)
 Other and mixture 6 (2.0) 7 (2.3)
 No therapist 16 (5.4) 33 (11.1)
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Similar proportions of women reported receiving 
urinary incontinence surgery at each follow­up. 
Uptake of further non­surgical urinary incontinence 
care or treatment was also comparable between groups 
(table 7).
In the biofeedback PFMT group, the mean cost for 
each participant, taking into account the intervention 
cost and continence related healthcare (hospital, 
primary care, prescribed drugs) during 24 months 
of follow­up was £1261 ($1605; €1374) (SD £1333) 
compared with £1118 (SD £1294) for the PFMT group 
(mean difference £121, 95% confidence interval 
−£409 to £651, P=0.64). The mean quality adjusted 
life years for biofeedback PFMT was 1.57 (SD 0.49) 
and for PFMT was 1.62 (SD 0.46) (−0.04, −0.12 to 
0.04, P=0.28). On average, biofeedback PFMT cost 
more than PFMT, and quality adjusted life years were 
lower, although the differences between groups were 
not statistically significant.
discussion
Our findings did not show a statistically significant 
or clinically important difference in severity of 
urinary incontinence at 24 months between women 
randomised to electromyographic biofeedback (in the 
clinic and at home) PFMT or to PFMT alone. These 
findings remained in subgroup analyses irrespective 
of urinary incontinence type, age, severity, or therapist 
type, and sensitivity analyses showed our primary 
outcome analysis was robust to missing data and non­
compliance. Across all secondary urinary outcomes 
(cure or improvement, other lower urinary tract 
symptoms, condition specific quality of life, patient 
perception of urinary incontinence improvement) 
at the 24 month follow­up, a consistent pattern of 
no difference between groups was observed. Other 
clinically focused secondary outcomes (pelvic floor 
muscle function, prolapse symptoms, and uptake 
of other urinary incontinence treatment) did not 
show any statistically significant differences between 
groups. Improvement in urinary incontinence was 
observed in both trial groups, with 8% of women in 
each group reporting cure and 60% in the biofeedback 
PFMT group and 63% in the PFMT group reporting 
improvement at 24 months. This degree of improve­
ment is consistent with the recently updated Cochrane 
table 3 | summary of international consultation on incontinence Questionnaire-urinary incontinence short form (iciQ-ui 
sF) responses of participants assigned to pelvic floor muscle training (PFMt) with electromyographic biofeedback or to 
PFMt alone, and differences between groups
time point
no of women, mean (sD)
Mean difference* (95% ci)biofeedback PFMt PFMt
Baseline 291, 12.5 (4.1) 294, 12.3 (3.7) –
Follow-up (months):
 6 221, 9.0 (5.0) 221, 8.8 (4.5) 0.39 (−0.33 to 1.12)
 12 249, 9.1 (4.9) 252, 8.7 (5.0) 0.57 (−0.17 to 1.31)
 24 225, 8.2 (5.1) 235, 8.5 (4.9) −0.09 (−0.92 to 0.75)
*Linear mixed models adjusted for minimisation variables, therapist type, and baseline ICIQ-UI SF.
Overall treatment effect
UI type
  Stress UI
  Mixed UI
Age (years)
  <50
  ≥50
Severity
  Mild/moderate UI (ICIQ-UI SF score <13)
  Severe UI (ICIQ-UI SF score ≥13)
Therapist type
  Not physiotherapist
  Physiotherapist
-0.09 (-0.92 to 0.75)
-0.80 (-2.13 to 0.53)
0.38 (-0.69 to 1.45)
-0.23 (-1.32 to 0.87)
0.12 (-1.17 to 1.40)
-0.75 (-2.03 to 0.53)
0.28 (-0.87 to 1.43)
1.15 (-1.38 to 3.68)
-0.24 (-1.12 to 0.64)
-3 -2 -1 1 20 3 4
Subgroup
analysis
Favours
biofeedback PFMT
Favours
PFMT
Estimate
(95% CI)
1.18 (-0.53 to 2.89)
0.34 (-1.35 to 2.03)
1.03 (-0.69 to 2.75)
-1.39 (-4.07 to 1.29)
Treatment effect Interaction effect
0.18
0.69
0.24
0.31
P value 
Estimate (95% CI)
Fig 2 | summary of subgroup analyses of primary outcome (international consultation on incontinence Questionnaire-urinary incontinence short 
form (iciQ-ui sF) response at 24 months). PFMt=pelvic floor muscle training
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review comparing PFMT with no treatment or inactive 
control.4 Our findings indicate that supervised and 
protocolised PFMT, with or without electromyographic 
biofeedback, provides benefit, supporting the current 
grade A recommendation for PFMT as an effective 
treatment for urinary incontinence.22 We observed 
greater PFMT self­efficacy in the biofeedback 
PFMT group, supporting the hypothesised effect of 
biofeedback. The group difference, however, was 
small and clinical significance uncertain. Further 
investigation into the role of self­efficacy is required. 
The findings of the economic analysis suggest that 
both interventions resulted in similar overall costs and 
quality of life over the follow­up period.
strengths and limitations of this study
One of the trial’s strengths was its large sample 
size, which was more than double that of the largest 
previous biofeedback trial,23 and large enough to 
detect a clinically important between group difference 
table 5 | lower urinary tract symptoms in participants assigned to pelvic floor muscle training (PFMt) with 
electromyographic biofeedback or to PFMt alone
no of women, mean (sD)
Mean difference* (95% ci)biofeedback PFMt PFMt
iciQ-Fluts
Filling score (range 0-15):
 Baseline 289, 5.0 (2.8) 297, 4.8 (2.6)
 6 months 183, 3.7 (2.7) 176, 3.4 (2.3)
 12 months 187, 3.8 (2.7) 186, 3.6 (2.4)
 24 months 167, 3.4 (2.6) 168, 3.5 (2.3) −0.19 (−0.61 to 0.24)
Voiding score (range 0-12):
 Baseline 292, 2.0 (2.0) 294, 2.0 (2.1)
 6 months 182, 1.6 (1.8) 179, 1.4 (1.8)
 12 months 188, 1.5 (1.9) 186, 1.5 (1.8)
 24 months 165, 1.6 (1.8) 169, 1.6 (1.8) 0.04 (−0.30 to 0.38)
Incontinence score (range 0-20):
 Baseline 290, 9.8 (3.6) 294, 9.3 (3.4)
 6 months 182, 7.1 (4.0) 178, 6.6 (3.8)
 12 months 188, 7.1 (3.9) 182, 6.6 (4.1)
 24 months 164, 7.0 (4.3) 169, 6.5 (4.0) 0.20 (−0.58 to 0.98)
iciQ-lutsqol
Overall (range 19-76):
 Baseline 292, 43.5 (12.3) 297, 42.3 (12.1)
 6 months 183, 36.2 (13.2) 176, 35.7 (11.9)
 12 months 189, 35.7 (13.3) 184, 34.7 (12.1)
 24 months 164, 34.3 (12.4) 169, 34.3 (12.5) −0.81 (−3.03 to 1.41)
Interference scale (range 0-10):
 Baseline 288, 7.4 (2.6) 288, 7.6 (2.5)
 6 months 183, 4.3 (3.1) 177, 4.3 (2.8)
 12 months 189, 4.0 (3.1) 184, 3.9 (3.0)
 24 months 163, 3.8 (3.1) 169, 3.7 (2.9) 0.26 (−0.33 to 0.85)
ICIQ-FLUTS=International Consultation on Incontinence Questionnaire-female lower urinary tract symptoms; ICIQ-LUTSqol=International Consultation on 
Incontinence Questionnaire-lower urinary tract symptoms quality of life.
*Between group differences only estimated at 24 months.
table 4 | cure and improvement of urinary incontinence in participants assigned to pelvic floor muscle training (PFMt) 
with electromyographic biofeedback or to PFMt alone
Outcome at follow-up
no with outcome/no in group (%)
Odds ratio* (95% ci)biofeedback PFMt PFMt
Cure†:
 6 months 12/221 (5.4) 13/223 (5.8) –
 12 months 16/250 (6.4) 22/253 (8.7) –
 24 months 18/229 (7.9) 20/238 (8.4) 0.90 (0.46 to 1.78)
Improvement‡:
 6 months 129/221 (58.4) 133/221 (60.2) –
 12 months 148/249 (59.4) 163/252 (64.7) –
 24 months 135/225 (60.0) 147/235 (62.6) 0.89 (0.61 to 1.32)
“Very much better” or “much better”§:
 6 months 96/219 (43.8) 85/221 (38.5) –
 12 months 101/249 (40.6) 92/250 (36.8) –
 24 months 93/227 (41.0) 90/236 (38.1) 1.12 (0.76 to 1.63)
*Between group differences only estimated at 24 months.
†Negative response to both “how often do you leak urine?” and “how much urine do you usually leak?”
‡Reduction in International Consultation on Incontinence Questionnaire-urinary incontinence short form of ≥3 points from baseline.
§Patient Global Impression of Improvement instrument.
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if one existed. The study therefore provides robust 
results to inform clinical practice. We recruited 
participants from various outpatient and community 
settings, and the two groups were highly comparable 
at baseline, increasing the generalisability of our 
findings. We standardised intervention delivery as 
far as possible, with therapists receiving face­to­
face training from clinical research team members 
along with a comprehensive intervention manual. 
Importantly, unlike previous trials, both groups 
received the same PFMT intervention making this a 
fair test of the benefits of adding electromyographic 
biofeedback. We achieved high questionnaire return 
rates (78% at 24 months) reducing the risk of attrition 
bias. Furthermore, our estimates of the treatment effect 
were robust to sensitivity analyses. We were unable to 
mask group allocation from participants, therapists, 
or researchers and consequently there was a potential 
risk of detection bias. Participants might have 
perceived their allocated treatment as being better or 
worse than that allocated to the other group. However, 
as adherence to appointments and home PFMT 
was similar for both groups, group allocation does 
not seem to have influenced women’s engagement. 
Masking of therapists was achieved in 93% of the 
six month PFM assessments, and results relating to 
these assessments showed no group differences. The 
attendance rate for these assessments was, however, 
lower than the questionnaire return rate, albeit similar 
between groups (51% in the biofeedback PFMT group, 
55% in the PFMT group). We excluded women who 
were unable to contract their pelvic floor muscles 
based on guidance that such women should be offered 
biofeedback.2 Consequently, conclusions cannot be 
drawn about this subpopulation. Newer devices have 
become available since the trial started, which utilise, 
for example, Bluetooth technology; however, the basic 
mechanism of biofeedback (giving a visual or auditory 
signal of an invisible physiological process) is the same 
regardless of the device type, and thus findings can be 
extrapolated.
comparison with other studies
Since this trial commenced several others evaluating 
biofeedback for the treatment of urinary incontinence 
have been published. Five are directly comparable, but 
are smaller single centre trials and have shorter follow­
up. One of the studies found no group differences in 
King’s Health Questionnaire parameters (measuring 
urinary incontinence related quality of life) after 12 
weeks when electromyographic biofeedback PFMT 
was compared with PFMT for women with stress 
urinary incontinence (n=46).24 Conversely, another of 
the studies found between group differences in favour 
of pressure biofeedback PFMT compared with PFMT in 
women with stress urinary incontinence on all but one 
King’s Health Questionnaire domain after 12 weeks 
(n=40).25 A further trial by the researchers found that 
women with stress urinary incontinence (n=72) were 
no more likely to increase the frequency of home 
exercise after three months, irrespective of whether 
they had home PFMT with clinic pressure biofeedback, 
or home and clinic PFMT, and cure did not differ 
at nine months.26 Electromyographic biofeedback 
with PFMT has, however, been found to statistically 
significantly improve pelvic floor muscle strength 
compared with PFMT alone for women with stress 
urinary incontinence (n=49).27 In a three arm trial in 
women with stress urinary incontinence (n=53), the 
addition of electromyographic perineal biofeedback 
or intravaginal pressure biofeedback to home PFMT 
were both superior to home PFMT alone for outcomes 
table 6 | Pelvic floor muscle assessment at baseline and six months (blinded) in 
participants assigned to pelvic floor muscle training (PFMt) with electromyographic 
biofeedback or PFMt alone. values are numbers (percentages) unless stated otherwise
Pelvic floor muscle assessment biofeedback PFMt PFMt
Oxford scale: slow contraction strength
Baseline: n=300 n=300
 1 34 (11.3) 31 (10.3)
 2 115 (38.3) 111 (37.0)
 3 128 (42.7) 134 (44.7)
 4 22 (7.3) 24 (8.0)
 5 1 (0.3) 0 (0.0)
Six months: n=153 n=166
 1 4 (2.6) 3 (1.8)
 2 25 (16.3) 23 (13.9)
 3 57 (37.3) 74 (44.6)
 4 54 (35.3) 56 (33.7)
 5 13 (8.5) 10 (6.0)
No of women, mean (SD) contraction endurance*:
 Baseline 264, 6.48 (3.00) 250, 6.35 (3.13)
 6 months 152, 8.72 (2.26) 166, 8.54 (2.48)
No of women, mean (SD) No of slow contractions†:
 Baseline 263, 6.03 (2.44) 249, 5.77 (2.41)
 6 months 151, 7.42 (2.62) 165, 7.55 (2.59)
*Length of hold (seconds).
†Repetitions to fatigue.
table 7 | uptake of further treatment for urinary incontinence in participants assigned to pelvic floor muscle training 
(PFMt) with electromyographic biofeedback or PFMt alone
Further treatment at follow-up
no with event/no in group (%)
Odds ratio (95% ci)biofeedback PFMt PFMt
Surgery:
 0-6 months 2/172 (1.2) 3/164 (1.8) 0.56 (0.09 to 3.53)
 6-12 months 8/204 (3.9) 11/210 (5.2) 0.63 (0.23 to 1.69)
 12-24 months 8/154 (5.2) 12/162 (7.4) 0.62 (0.24 to 1.65)
Non-surgical treatment:
 0-6 months 96/146 (65.8) 107/149 (71.8) 0.77 (0.46 to 1.28)
 6-12 months 70/164 (42.7) 74/159 (46.5) 0.90 (0.56 to 1.42)
 12-24 months 40/105 (38.1) 42/119 (35.3) 0.65 (0.65 to 2.03)
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relating to severity of urinary incontinence, cure or 
improvement, and pelvic floor muscle strength.28
Policy implications and conclusions
Overall, the trial findings are consistent with national 
guidelines and confirm the recommendation that 
electromyographic biofeedback should not be rou­
tinely offered as part of PFMT.2
In this large multicentre trial with long term follow­
up of electromyographic biofeedback as an adjunct to 
PFMT, we found no evidence of benefit from routinely 
adding biofeedback to PFMT. Supervised PFMT is 
effective in the management of urinary incontinence, 
although further research is needed into how to 
maximise its benefits.
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